

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

6 References

1. TECVAYLI (teclistamab-cqyv). In. Horsham, PA: Janssen Biotech, Inc; 2022.
2. TECVAYLI (teclistamab). In. Leiden, The Netherlands: Janssen Biologics BV; 2022.
3. Palumbo A, Anderson K. Multiple myeloma. *N Engl J Med*. 2011;364(11):1046-1060.
4. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. *Lancet*. 2021;397(10272):410-427.
5. Noll JE, Williams SA, Tong CM, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. *Haematologica*. 2014;99(1):163-161S171.
6. Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. *Blood Cancer J*. 2018;8(3):26.
7. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. *JAMA*. 2022;327(5):464-477.
8. de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. *Biomed Res Int*. 2014;2014:232546.
9. Kamal M, Wang XS, Shi Q, et al. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. *Support Care Cancer*. 2021;29(1):467-475.
10. Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. *Eur J Haematol*. 2016;97(5):416-429.
11. Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. *BMC Cancer*. 2016;16:427.
12. Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. *Arch Neurol*. 2004;61(9):1423-1429.
13. Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. *Blood Cancer J*. 2021;11(2):40.
14. National Cancer Institute. Cancer stat facts: myeloma. <https://seer.cancer.gov/statfacts/html/mulmy.html>. Accessed April 26, 2023.
15. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol*. 2019;37(14):1228-1263.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

16. Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. *Blood Rev.* 2021;49:100808.
17. Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. *Int J Mol Sci.* 2021;22(9):4462.
18. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer.* 2020;20(1):1087.
19. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood.* 2011;117(18):4691-4695.
20. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. *Leukemia.* 2022;36(5):1371-1376.
21. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia.* 2019;33(9):2266-2275.
22. Branagan A, Lei M, Lou U, Raje N. Current treatment strategies for multiple myeloma. *JCO Oncol Pract.* 2020;16(1):5-14.
23. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. *Haematologica.* 2020;105(10):2358-2367.
24. Oriol A. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Poster presented at European Hematology Association (EHA) 2024 Hybrid Congress; June 13–16, 2024; Madrid, Spain.
25. Heider M, Nickel K, Hogner M, Bassermann F. Multiple myeloma: molecular pathogenesis and disease evolution. *Oncol Res Treat.* 2021;44(12):672-681.
26. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. *Am Fam Physician.* 2017;95(6):373-383.
27. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. *J Clin Oncol.* 2016;34(13):1544-1557.
28. Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. *Cancer Growth Metastasis.* 2014;7:33-42.
29. Egan PA, Elder PT, Deighan WI, O'Connor SJM, Alexander HD. Multiple myeloma with central nervous system relapse. *Haematologica.* 2020;105(7):1780-1790.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

30. Jurczynszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. *Am J Hematol*. 2016;91(6):575-580.
31. CARVYKTI (ciltacabtagene autoleucel) [press release]. Horsham, PA: Janssen Biotech, Inc. 2022.
32. ABECMA (idecabtagene vicleucel). In. Summit, NJ: Bristol-Myers Squibb Company; 2021.
33. THALOMID (thalidomide). In. Summit, NJ: Celgene Corporation; February 2021.
34. REVLIMID (lenalidomide). In. Summit, NJ: Celgene Corporation; August 2021.
35. POMALYST (pomalidomide). In. Summit, NJ: Celgene Corporation; December 2020.
36. VELCADE (bortezomib). In. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November 2021.
37. KYPROLIS (carfilzomib). In. Thousand Oaks, CA: Amgen, Inc.; November 2021.
38. NINLARO (ixazomib). In. Cambridge, MA: Takeda Pharmaceutical Company Limited; March 2021.
39. SARCLISA (isatuximab-irfc). In. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; March 2021.
40. Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. *Cancers (Basel)*. 2021;13(4):863.
41. EMPLICITI (elotuzumab). In. Princeton, NJ: Bristol-Myers Squibb Company; 2015.
42. DARZALEX (daratumumab). In. Horsham, PA: Janssen Biotech, Inc.; March 2022.
43. TALVEY (talquetamab-tgvs). In. Horsham, PA: Janssen Biotech, Inc; 2023.
44. ELREXFIO (elranatamab-bcmm). In. New York, NY: Pfizer Inc.; 2023.
45. TALVEY (talquetamab). In. Beerse, Belgium Janssen-Cilag International NV; 2023.
46. ELREXFIO (elranatamab). In. Bruxelles, Belgium: Pfizer Europe MA EEIG; 2023.
47. Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma. *Ther Adv Hematol*. 2018;9(5):123-133.
48. Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. *Hematology Am Soc Hematol Educ Program*. 2017;2017(1):498-507.
49. Ackley J, Ochoa MA, Ghoshal D, Roy K, Lonial S, Boise LH. Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma. *Cancers (Basel)*. 2021;13(19):4787.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

50. Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. *Drugs*. 2017;77(5):505-520.
51. Ito S. Proteasome inhibitors for the treatment of multiple myeloma. *Cancers (Basel)*. 2020;12(2):375-386.
52. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015;372(2):142-152.
53. Lapietra G, Fazio F, Petrucci MT. Race for the cure: from the oldest to the newest monoclonal antibodies for multiple myeloma treatment. *Biomolecules*. 2022;12(8):1146.
54. van de Donk NWCJ, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. *Front Immunol*. 2018;9:2134.
55. Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. *Drugs*. 2018;78(1):19-37.
56. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. *Mol Ther Oncolytics*. 2016;3:16015.
57. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. *Biomark Res*. 2017;5:22.
58. Munshi NC, Anderson LD, Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med*. 2021;384(8):705-716.
59. Bristol Myers Squibb. US FDA approves Bristol Myers Squibb and 2seventy bio's Abecma for triple-class exposed relapsed or refractory multiple myeloma after two prior lines of therapy. <https://news.bms.com/news/details/2024/U.S.-FDA-Approves-Bristol-Myers-Squibb-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Relapsed-or-Refractory-Multiple-Myeloma-After-Two-Prior-Lines-of-Therapy/default.aspx>. Published 2024. Accessed June 18, 2024.
60. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. *J Clin Oncol*. 2023;41(6):1265-1274.
61. Johnson & Johnson. U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma. <https://www.jnj.com/media-center/press-releases/u-s-fda-oncologic-drugs-advisory-committee-recommends-carvykti-ciltacabtagene-autoleucel-for-the-earlier-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma>. Published 2024. Accessed June 18, 2024.
62. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021;398(10297):314-324.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

63. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. *Leukemia*. 2020;34(4):985-1005.
64. Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. *Blood Adv*. 2020;4(18):4538-4549.
65. Alhallak K, Sun J, Jeske A, et al. Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges. *Cancers (Basel)*. 2021;13(12):2853.
66. Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. *Front Immunol*. 2020;11:762.
67. Zhou X, Einsele H, Danhof S. Bispecific antibodies: a new era of treatment for multiple myeloma. *J Clin Med*. 2020;9(7):2166.
68. XPOVIO (selinexor) tablets [press release]. Newton, MA: Karyopharm Therapeutics Inc2019.
69. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med*. 2019;381(8):727-738.
70. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. *Br J Haematol*. 2016;175(2):252-264.
71. Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. *Drugs Context*. 2021;10:2021-2022-2024.
72. Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. *Front Immunol*. 2018;9:1821.
73. Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in multiple myeloma. *Cells*. 2020;9(3):601.
74. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. *Clin Cancer Res*. 2013;19(8):2048-2060.
75. Cho SF, Lin L, Xing L, et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. *Cancers (Basel)*. 2020;12(6):1473.
76. Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. *Clin Cancer Res*. 2013;19(8):1917-1919.
77. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. *J Hematol Oncol*. 2020;13(1):125.
78. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. *Immunotherapy*. 2015;7(11):1187-1199.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

79. Laurent SA, Hoffmann FS, Kuhn PH, et al. γ -Secretase directly sheds the survival receptor BCMA from plasma cells. *Nat Commun*. 2015;6:7333.
80. Moreau P. Updated results from MajesTEC-1: phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. Abstract presented at 63rd American Society of Hematology (ASH) Annual Meeting; December 11–14, 2021, 2021; Atlanta, GA & Virtual.
81. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. *EBioMedicine*. 2020;52:102625.
82. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. *Lancet*. 2021;398(10306):1157-1169.
83. Bashash D, Zandi Z, Kashani B, Pourbagheri-Sigaroodi A, Salari S, Ghaffari SH. Resistance to immunotherapy in human malignancies: mechanisms, research progresses, challenges, and opportunities. *J Cell Physiol*. 2022;237(1):346-372.
84. Strohl WR, Naso M. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. *Antibodies (Basel)*. 2019;8(3):41.
85. Frerichs KA, Broekmans MEC, Marin Soto JA, et al. Preclinical activity of JNJ-7957, a novel BCMA \times CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. *Clin Cancer Res*. 2020;26(9):2203-2215.
86. Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387(6):495-505.
87. Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen \times CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. *Lancet*. 2021;398(10301):665-674.
88. Johnson & Johnson. Janssen announces U.S. FDA breakthrough therapy designation granted for teclistamab for the treatment of relapsed or refractory multiple myeloma. https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-teclistamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma#_edn1. Published 2021. Accessed May 30, 2023.
89. Johnson & Johnson. European Commission approves reduced dosing frequency for Janssen's bispecific antibody TECVAYLI® (teclistamab). <https://www.jnj.com/media-center/press-releases/european-commission-approves-reduced-dosing-frequency-for-janssens-bispecific-antibody-tecvayli-teclistamab#:~:text=BEERSE%2C%20Belgium%2C%2018%20August%202023%20%E2%80%93%20The%20Janssen,better%20for%20a%20minimum%20of%20six%20months.%20>. Published 2023. Updated August 18, 2024. Accessed April 23, 2024.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

90. Johnson & Johnson. TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma. https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-us-fda-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-302066627.html?tc=eml_cleartime. Published 2024. Updated February 20, 2024. Accessed March 14, 2024.
91. Costa LJ. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma with high-risk features: a subgroup analysis from the phase 1/2 MajesTEC-1 study. European Hematology Association (EHA) 2024 Congress; June 13–16, 2024, 2024; Madrid, Spain.
92. Jagosky MH, Usmani SZ. Extramedullary disease in multiple myeloma. *Curr Hematol Malig Rep*. 2020;15(2):62-71.
93. van de Donk NW. Teclistamab in relapsed or refractory multiple myeloma (RRMM): MajesTEC-1 subgroup analysis by lines of therapy. Abstract presented at Brazilian Congress of Hematology, Hemotherapy and Cell Therapy (HEMO); October 25–28, 2023, 2023; Sao Paulo, Brazil.
94. Nooka AK. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): updated efficacy and safety results from MajesTEC-1. Abstract presented at American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL & Virtual.
95. Garfall AL. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Abstract presented at American Society of Clinical Oncology (ASCO) Annual Meeting; May 31–June 4, 2024, 2024; Chicago, IL.
96. Brioli A, Klaus M, Sayer H, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. *Ann Hematol*. 2019;98(3):713-722.
97. Nooka A. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. *Cancer*. 2023:1–15.
98. Martin TG, Mateos MV, Nooka A, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. *Cancer*. 2023.
99. Cortes-Selva D. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: correlative analyses from MajesTEC-1. Abstract presented at 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022, 2022; New Orleans, LA.
100. Touzeau C. Efficacy and safety of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma after exposure to other BCMA-targeted agents. 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022, 2022; Chicago, IL/Virtual.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

101. Rodriguez-Otero P. A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for daratumumab in combination with teclistamab (a B-cell maturation antigen x CD3 bispecific antibody). Abstract presented at American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL & Virtual.
102. Mateos MV. MajesTEC-3: randomized phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. Abstract presented at American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022, 2022; Chicago, IL & Virtual.
103. Cohen Y. Talquetamab + teclistamab in patients (pts) with relapsed/refracotry multiple myeloma (RRMM): Updated phase 1B results from REDIRECTT-1 with >1 year of follow-up. Abstract presented at European Hematology Association (EHA) 2024 Hybrid Congress; June 13–16, 2023; Madrid, Spain.
104. van de Donk NW. Safety results from the phase 3 MajesTEC-7 study in patients with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM). Abstract presented at European Hematology Association (EHA) 2024 Hybrid Congress; June 13–16, 2024, 2024; Madrid, Spain.
105. European Medicines Agency. New medicine for multiple myeloma patients with limited treatment options. European Medicines Agency.
<https://www.ema.europa.eu/en/news/new-medicine-multiple-myeloma-patients-limited-treatment-options>. Published 2022. Accessed May 30, 2023, 2023.
106. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma [press release]. US Food and Drug Administration2022.
107. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. *Blood*. 2004;103(8):3148-3157.
108. Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. *Clin Cancer Res*. 2007;13(19):5903-5909.
109. Cortes-Selva D, Perova T, Skerget S, et al. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1. *Blood*. 2024; Online ahead of print. .
110. Moreau P. Comparative effectiveness of teclistamab versus real-world physician's choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed/refractory multiple myeloma. *Adv Ther*. 2023;41(2):696–715.
111. Krishnan A. Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma. Abstract presented at International Society for Pharmacoeconomics and

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

- Outcomes Research Europe (ISPOR EU) Annual Meeting; November 12–15, 2023, 2023; Copenhagen, Denmark.
112. Moreau P. Matching-adjusted indirect treatment comparison of teclistamab vs approved therapies for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma. Abstract presented at 19th International Myeloma Society (IMS) Annual Meeting; August 25–27, 2022, 2023; Los Angeles, CA.
 113. Moreau P. Matching-adjusted indirect treatment comparison of teclistamab versus selinexor-dexamethasone for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma. Abstract presented at International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR EU) Annual Meeting; November 12–15, 2023, 2023; Copenhagen, Denmark.
 114. Mol I. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. *Leukemia & Lymphoma*. 2024;65(5):660-668.
 115. Jagannath S. Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Abstract presented at American Society of Clinical Oncology (ASCO) Annual Meeting; May 31–June 4, 2024, 2024; Chicago, IL & Virtual.
 116. Engelhardt M, Ihorst G, Singh M, et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. *Clin Lymphoma Myeloma Leuk*. 2021;21(2):e160-e175.
 117. Martin T. Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study. *Clin Lymphoma Myeloma Leuk*. 2024;24(3):194-202.
 118. Martin T. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with teclistamab, a B-cell maturation antigen x CD3 bispecific antibody: patient-reported outcomes in MajesTEC-1. Abstract presented at American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022, 2023; Chicago, IL & Virtual.
 119. Goldschmidt H, Ashcroft J, Szabo Z, Garderet L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? *Ann Hematol*. 2019;98(1):1-18.
 120. Krejci J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. *Blood*. 2016;128(3):384-394.
 121. Zamagni E. MajesTEC-4 (EMN30): a phase 3 trial of teclistamab + lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Abstract presented at 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.

122. Cohen YC, Oriol A, Wu KL, et al. Daratumumab with cetrelimab, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk.* 2021;21(1):46-54.e44.
123. Fernandez de Larrea C, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted car t-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. *Blood Cancer Discov.* 2020;1(2):146-154.
124. Searle E. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase 1b, multicohort study. Abstract presented at 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA.
125. Hucks G, Rheingold SR. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. *Blood Cancer J.* 2019;9(2):10.
126. Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. *Acta Pharm Sin B.* 2018;8(4):539-551.
127. Anderson LD, Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. *Future Oncol.* 2022;18(3):277-289.
128. Kourelis T, Bansal R, Berdeja J, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. *Transplant Cell Ther.* 2023;29(4):255-258.
129. Bittner B, Richter W, Schmidt J. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. *BioDrugs.* 2018;32(5):425-440.
130. Sanchez-Felix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. *Adv Drug Deliv Rev.* 2020;167:66-77.
131. Slavcev M, Spinelli A, Absalon E, et al. Results of a time and motion survey regarding subcutaneous versus intravenous administration of daratumumab in patients with relapsed or refractory multiple myeloma. *Clinicoecon Outcomes Res.* 2021;13:465-473.
132. Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. *Ann Pharmacother.* 2013;47(9):1136-1142.
133. Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematol.* 2020;7(5):e370-e380.
134. Usmani SZ. Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study. Abstract presented at American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6, 2023; Chicago, IL & Virtual.

TECVAYLI® (teclistamab-cqyv) US Prix Galien submission. June 30, 2024.